Form 4: Acrivon Therapeutics Executive Erick Gamelin Reports Stock Disposal for Tax Obligations
SEC Form 4 Filing
Chief Development Officer Erick Gamelin of Acrivon Therapeutics reports disposing of 402 shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On May 14, 2024, Erick Gamelin, Chief Development Officer of Acrivon Therapeutics, Inc., disposed of 402 shares of common stock to satisfy tax withholding requirements.
- The shares were disposed of at a price of $8.36 per share.
- Following the transaction, Gamelin directly owns 17,765 shares of Acrivon Therapeutics.
Sentiment
Score: 5
Explanation: This is a neutral event, reflecting a standard transaction for tax purposes. It doesn't indicate a positive or negative outlook for the company.
Industry Context
Form 4 filings are standard disclosures required by the SEC for insiders of publicly traded companies, providing transparency into their transactions in the company's stock. This is a routine transaction related to tax obligations.
Stakeholder Impact
- The transaction has minimal impact on stakeholders as it is a routine disposal of shares for tax purposes.
Key Dates
| Date | Description |
|---|---|
| 05/14/2024 | Date of stock disposal transaction |
| 05/16/2024 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.